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 Abstract 
 
Current understanding and treatment of depression is limited to the monoaminergic theory with 
little knowledge of the involvement of other cellular processes. GWAS however implicate several 
novel SNPs with weak but replicable effects and unclarified mechanisms. We investigated the effect 
of rs1106634 of the ATPV1B2 gene encoding the vacuolar H+ATP-ase on lifetime and current 
depression and the possible mediating role of neuroticism by logistic and linear regression in a white 
European general sample of 2226 subjects. Association of rs1106634 with performance on frontal 
(SOC) and hippocampal dependent (PAL) cognitive tasks was investigated in multivariate general 
linear models in a smaller subsample.   
The ATP6V1B2 rs1106634 A allele had a significant effect on lifetime but not on current 
depression. The effect of the A allele on lifetime depression was not mediated by neuroticism. The A 
allele influenced performance on the PAL but not on the SOC test. We conclude that the effects of 
variation in the vacuolar ATP-ase may point to a new molecular mechanism that influences the long-
term development of depression. This mechanism may involve dysfunction specifically in 
hippocampal circuitry and cognitive impairment that characterizes recurrent and chronic depression.  
 
 
key words: Depression, vacuolar ATP-ase, ATP6V1B2, rs1106634, neurocognitive deficits, 
hippocampal dysfunction 
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1. Introduction  
 
Major depression has a great burden both in terms of suffering and costs for the society 1-5. 
However, its pathology is still unclear. There is a strong genetic background with risk of first-degree 
relatives showing a 2.8-fold increase 6-8 and twin studies suggesting a 37-43% heritability 7.  
Due to its exceptionally large clinical heterogeneity depression is difficult to study from a genetic 
point of view 6. Candidate gene studies select polymorphisms based on linkage studies or 
hypothetical choices concerning already known etiological mechanisms in the neurobiology of 
depression. Therefore the scope of investigated polymorphisms is rather narrow in terms of the 
systems in question 9. Consistently replicated findings from these studies are few and the identified 
polymorphisms confer a small amount of risk. In contrast to association studies limited to previous 
knowledge and researcher preferences, GWAS-s (genome-wide association studies) are more 
comprehensive and less biased. However, as a major drawback genome-wide significance needs to 
be set to very low due to the large amount of hypothesis testing. Furthermore, polymorphisms 
implicated in GWAS studies with at least a suggestive significance often show no connection to 
mechanisms already implicated in the background of depression 6. 
Although one novel study using a very large cohort but less intensive phenotyping  based on 
self-reported depression identified 15  genetic loci, 10 generally no associations with a genome-wide 
significance are identified in individual studies in psychiatric patients.  A recent meta-analysis of 
three GWAS-s in major depressive disorder observed the strongest associations for three intronic 
SNPs, including one (rs1106634) in the ATP6V1B2 gene (Figure 1) encoding the B subunit of the 
vacuolar H+ pump ATP-ase with a suggestive significance (p=6.78 x 107) for the A allele 11. In another 
large meta-analysis in schizophrenia and bipolar disorder rs1106634 also exhibited a suggestive p 
value (3.97x10-6) although for the opposite, T allele 12.  The cytosolic domain where this subunit is 
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located is part of a transmembrane complex playing a role in the generation of H+ gradients across 
synaptic vesicle membranes and is a key player in receptor-mediated endocytosis 11.  
With our current understanding and treatment approaches in depression mainly confined to 
monoaminergic theory and far less than adequate due to limited efficacy and significant side effects, 
it would be valuable to investigate SNPs with a weak but replicable effect in GWAS-s to identify new 
molecules of vulnerability, mechanisms of etiopathology and targets of treatment. In our study we 
investigated the association of rs1106634 and depression-related phenotypes including lifetime and 
current depression as well as hippocampal and prefrontal-related neurocognitive deficits in a large, 
general, nonclinical sample in Manchester and Budapest.  
 
2. Materials and Methods 
This present research is part of the NewMood study, funded by the European Union (New 
Molecules in Mood Disorders, Sixth Framework Program of the EU, LSHM-CT-2004-503474), carried 
out in accordance with the Declaration of Helsinki, and approved by the local Ethics Committees 
(Scientific and Research Ethics Committee of the Medical Research Council, Budapest, Hungary; and 
North Manchester Local Research Ethics Committee, Manchester, United Kingdom).  
 
2.1. Participants 
All participants provided written informed consent. 
Our study involved two levels, 1 and 2. Level-1 sample was recruited through advertisements and 
general practices in Budapest, and through advertisements, general practices, and a website in 
Greater Manchester. N=2226 subjects (n=904 in Budapest and n=1322 in Manchester) were 
successfully genotyped for ATP6V1B2 rs1106634, and provided information about gender, age, 
lifetime and current depression by filling out the NewMood questionnaire pack 13. All Level-1 subjects 
were of white European ethnic origin, and had no relatives participating.  
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Level-2 sample was collected in Manchester. N=206 subjects (n=114 having participated in 
Level-1; and n=92 new subjects recruited through advertisements) were successfully genotyped for 
ATP6V1B2 rs1106634 and interviewed for Montgomery-Åsberg Depression Rating Scale and lifetime 
depression, provided information about gender, age and neuroticism, and carried out both cognitive 
tasks. 
 
2.2. Phenotypic assessment 
Level-1 questionnaire pack included the Brief Symptom Inventory (BSI) 14, the Big Five Inventory (BFI-
44) 15, and a background questionnaire containing a question about lifetime depression, validated 
with face-to-face diagnostic interviews in a subsample 13. We calculated a continuous weighted score 
(sum of item scores divided by number of items completed) for the BSI-depression subscale 
(depression items plus additional items) (BSI-Dep), and for the BFI-44 neuroticism scale and used 
these variables for the analyses.  
In Level-2, we measured lifetime depression with a clinical diagnosis of major depressive 
disorder: trained researchers administered the Structured Clinical Interview for DSM-IV (SCID-I/NP) 
16. Those with bipolar disorder or any other psychiatric condition except for major depression were 
excluded from the analyses. Montgomery-Åsberg Depression Rating Scale (MADRS) was used to 
measure depressive symptoms 17. Neuroticism was measured with the neuroticism subscale of the 
NEO-PI-R 18.  
In Level-2, to assess neurocognitive endophenotypes of depression we chose two computerized 
tasks from the Cambridge Neuropsychological Test Automated Battery software (CANTAB; 
http://www.cambridgecognition.com/). Paired Associates Learning (PAL) task assesses episodic 
memory, thus medial temporal lobe functioning, by requiring the subject to learn paired associations 
between a visual pattern and a spatial location (http://www.cambridgecognition.com/tests/paired-
associates-learning-pal), and indicated a hippocampal dysfunction in depression (Michopoulos et al, 
2008) and other neuropsychiatric disorders 19, 20. Three scores were calculated and used in our 
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analyses: memory score on the first trial (PAL-memory score), total number of errors (PAL-errors), 
and total number of trials (PAL-required trials). The other task, Stockings of Cambridge (SOC) 
measures frontal lobe function by a test of spatial planning and spatial working memory 
(http://www.cambridgecognition.com/tests/stockings-of-cambridge-soc), and is sensitive to 
executive deficits in depression 21, 22. We calculated and analyzed two scores of SOC: mean of all 
initial thinking times throughout the SOC task (SOC-ITT), and rate of problems solved in minimum 
moves (SOC-correct trial rate).  
 
2.3. Genotyping 
Participants provided buccal mucosa cells using a genetic saliva sampling kit. We extracted genomic 
DNA according to 23. ATP6V1B2 rs1106634 was genotyped with Sequenom MassARRAY technology 
(Sequenom, San Diego, www.sequenom.com). All laboratory work was performed under 
ISO9001:2000 quality management requirements, and blinded for phenotype. 
 
2.4. Statistical analyses 
We used PLINK v1.07 (http://pngu.mgh.harvard.edu/purcell/plink/) to calculate Hardy-Weinberg 
equilibrium and to build regression models in Level-1. Logistic regression equations were run on 
lifetime depression, and linear regressions on BSI-depression score, in additive, dominant and 
recessive models, with ATP6V1B2 rs1106634, population (Budapest or Manchester), gender and age 
as predictors. Bonferroni-corrected significance threshold was p≤0.0083 for these six analyses. As 
post hoc tests in Level-1, with a nominal p≤0.05 significance threshold, we intended to replicate the 
significant findings in the Budapest and Manchester subsamples, separately. Also as post hoc tests 
we tested the putative mediating effect of neuroticism in the combined Level-1 
Budapest+Manchester sample for the significant findings, including it as an additional predictor in 
the regression equations. 
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IBM SPSS Statistics 23 was used for descriptive statistics, and to test post hoc effect of 
ATP6V1B2 rs1106634 on PAL and SOC performance in Level-2. We built a multivariate general linear 
model for the three PAL outcomes, and another one for the two SOC outcomes, with ATP6V1B2 
rs1106634 as a fixed factor and gender, age, lifetime depression, MADRS score and NEO-PI-R 
neuroticism score as covariates in both models. A nominal p≤0.05 significance threshold was applied. 
Similar multivariate models, but without rs1106634, were used to gain residuals for the task 
performance variables in order to visualize the genetic effect on them in the figures. 
Quanto (http://biostats.usc.edu/Quanto.html) was used to calculate the power of the main six 
tests, giving the Bonferroni-corrected p≤0.0083 as type I error rate. Power to detect main genetic 
effects on lifetime depression is moderate or low: assuming an odds ratio (OR) of 1.2 and a 
population prevalence of 15% for lifetime depression, the power in our sample is 50.31% in a log-
additive, 29.98% in a dominant, and 5.79% in a recessive model. The power is high to detect genetic 
main effects on BSI-depression score (of which mean is 0.87 and standard deviation is 0.931 in our 
sample, and n=2222, assuming an R2=1%): the power is 98.15% in all three models. 
Individually written R-scripts 24 were applied in the PLINK analysis of the Level-1 subsamples to 
perform the separate analyses in the Budapest and Manchester subsamples.    
  
3. Results  
3.1. Description of the sample 
 
Rs1106634 A is the minor allele in our sample. Our sample was in Hardy-Weinberg equilibrium 
(p>0.05).  
Description of the Level-1 and 2 samples is shown in Table 1. The Level-1 Budapest and 
Manchester subsamples differ significantly in all variables except for gender, so including population 
as a predictor in the regression equations is required. 
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3.2. Effect of the A allele on lifetime and current depression 
In the combined Level-1 sample, ATP6V1B2 rs1106634 A allele exerts a Bonferroni-corrected 
significant effect as a risk for lifetime depression in additive and dominant, but not in recessive 
models (Table 2). Nevertheless, its effect is not significant on BSI-depression score in any of the 
models (Table 2). Post hoc analyses indicated that the risk of the A allele on lifetime depression is 
replicable in the two subsamples (Table 3). 
 
3.3. The mediatory role of neuroticism 
We investigated whether the effect of ATP6V1B2 rs1106634 A allele on lifetime depression is due to 
the association of the A allele with higher neuroticism scores. In the combined Level-1 sample, with 
population, gender and age as covariates, A allele is in a significant positive association with 
neuroticism score (its β=0.102; t=2.724; p=0.006 in an additive, and β=0.114; t=2.721; p=0.007 in a 
dominant model). Lifetime depression also associates positively to neuroticism (t=-27.996; p<0.001): 
mean neuroticism score is 3.70±0.026 in those who did, and 2.75±0.022 in those who did not report 
lifetime depression. So, we could test the possible mediating role of neuroticism in the effect of the A 
allele on lifetime depression risk. As post hoc tests with a nominal p≤0.05 significance threshold, 
including neuroticism as an additional covariate in the regression equations, besides population, 
gender and age, the significant positive effect of A allele on lifetime depression risk decreased but 
did not disappear: OR=1.317; t=2.562; p=0.010 in the additive, and OR=1.367; t=2.622; p=0.009 in 
the dominant model (for comparisons, see Table 2), indicating that the effect of the A allele on 
depression is not mediated solely by the association of this allele with neuroticism. 
 
 
3.4. Association of the A allele with brain region-specific cognitive performance 
Next, we tested post hoc, in Level-2, if ATP6V1B2 rs1106634 A allele explains the variance of 
performance on the two neurocognitive tasks independently of the variance explained by lifetime 
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depression, current depression and neuroticism. A multivariate general linear model was built with A 
allele as a fixed factor (in a dominant model, because of low number in the AA group, see Table 1), 
gender, age, lifetime depression, MADRS and neuroticism as covariates, and PAL-memory score, PAL-
errors and PAL-required trials as the dependent variables. Wilks’ Lambda of the A allele showed F= 
5.661, p=0.001. The A allele exerted a nominally significant effect on each PAL variable in the model 
(PAL-memory: F=15.159; p<0.001; PAL-errors: F=9.350; p=0.003; PAL-required trials: F=8.546; 
p=0.004). Another multivariate general linear model was built with the A allele as a fixed factor (in a 
dominant model), gender, age, lifetime depression, current depression (MADRS) and neuroticism as 
covariates, and SOC-ITT and SOC-correct trial rate as dependent variables. For Wilks’ Lambda of the A 
allele, F=1.665; p=0.192. In this model, the A allele did not exert a significant effect on any of the SOC 
variables (SOC-ITT: F=0.612; p=0.435; SOC-correct trial rate: F=2.039; p=0.155) (Figure 2). 
 
4. Discussion  
In our study in a large general sample ATP6V1B2 rs1106634 A allele was a significant risk factor for 
lifetime major depression but was not associated with current depressive symptom manifestation. 
This risk effect of the A allele on depression was only partially mediated by neuroticism, a well-
known risk factor for depression, which was associated with both depression and the A allele in our 
study indicating overlapping genetic risk but different mechanisms. Furthermore, our results show 
that rs1106634 may exert a brain region-specific effect independently of lifetime history or current 
level of depression impacting temporal-hippocampal but not frontal functions as reflected by 
significantly decreased performance in A allele carriers on the PAL but not on the SOC 
neurocognitive. Our results thus show that ATP6V1B2 rs1106634 may play an important role in the 
long-term development and risk for depression, but not in its cross-sectional symptomatology, 
possibly via its effect on hippocampal function conceived to play a central role in depression. 
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4.1 Association of rs1106634 A allele with risk for lifetime depression but not current depressive 
symptoms 
In line with previous GWAS-s implicating the involvement of the ATP6V1B2 rs1106634 in affective 
disorders 11, 12, 25 we found a significant association between the A allele and lifetime depression in 
our large, average population of 2226 subjects and replicated our findings in two independent 
subsamples from Budapest and Manchester showing the involvement of this variant in the lifetime 
risk for depression. Interestingly, we found no association between this polymorphism and current 
depressive symptoms, indicating that this genetic variant is not associated directly with currently 
detectable symptoms but may be related to cellular mechanisms associated with the development of 
depression on brain functional or structural levels. Based on our findings rs1106634 is involved in the 
development of a trait-like risk for depression rather than its state-like manifestation. Furthermore, it 
is possible that consequences of the presence of the A allele are manifested in neurocognitive rather 
than mood symptoms of depression which are hypothesized to play a central role in depression but 
are not captured by conventional rating scales, and can be only detected by assessing neurocognitive 
performance, as indicated in our study by the significantly lower performance on the PAL test 
reflecting impaired hippocampal function in A allele carriers.    
 
4.2 Association of rs1106634 with lifetime risk of depression is not mediated by neuroticism 
The rs1106634 A allele was significantly associated with neuroticism, a well-established prospective 
risk factor for depression 26. Neuroticism is a personality trait of negative emotionality associated 
with less adaptive coping with inner and outer stressors and increased mood lability leading to a 
heightened risk of experiencing anxiety and depressed mood 27. Therefore, its presence is likely to 
play a developmental role in depression which further supports our notion that the A allele 
influences long-term adjustment and trait-like risk factors rather than state-like symptomatic 
presentation of depression. Although neuroticism is one of the most widely studied endophenotypes 
of depression with about 55% of shared genetic risk 28, we found that neuroticism only partially 
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mediated the effects of rs1106634 on lifetime depression. We conclude that rs1106634 may 
influence neuroticism and depression in ways that are partially independent. 
 
4.3 Association of rs1106634 with hippocampal but not prefrontal neurocognitive dysfunction 
In our study rs1106634 A allele was associated with hippocampal cognitive deficits indicated by 
decreased performance on all measures of the PAL task independently of lifetime or current 
depression and neuroticism, while prefrontal functions indicated by the SOC test remained intact. 
Thus our results raise the possibility that the effect of this polymorphism is area-specific affecting 
temporal rather than prefrontal lobe function. Given the role of the vacuolar ATPase in cellular 
function and the fact that the hippocampus is an area with high energy- and oxygen need and 
increased vulnerability compared to other regions 29-31, it is possible that this area is more sensitive to 
possible functional consequences of this polymorphic variant.  
PAL performance involves learning random visuospatial associations and is sensitive to 
hippocampal damage 20. Michopoulos et al reported that impaired PAL was associated with measures 
of the severity and chronicity of depression including illness duration and number of prior episodes. 
In contrast in the same study no such measures of depression chronicity were found to be associated 
with SOC scores 22. This is in line with our assumption that rs1106634 effects are reflected in lifetime 
rather than acute depression measures and are linked to long-term risk and development of 
depression.  
Our results indicating a specific association between hippocampal dysfunction and rs1106634 
are especially interesting as hippocampal dysfunction is thought to play a central role as part of a 
larger dysregulated circuitry implicated in the pathophysiology of depression 32, 33. Loss of 
hippocampal volume is associated with several measures of increased long-term depression severity 
and worse clinical outcome 33 and structural effects of genetic influences 34. The hippocampus is 
considered a brain region with increased sensitivity to stress 35 resulting in structural changes as well 
as enhanced vulnerability to metabolic insults 33 and depression is also a highly stress-associated 
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illness. Therefore, the possible consequences of genetically determined differences in vacuolar H+ 
ATP-ase may be especially manifested in the most vulnerable regions such as the hippocampus in 
high stress-associated illnesses such as depression. 
 
4.4 Possible mechanisms behind the role of rs1106634 in depression and hippocampal dysfunction 
Rs1106634 is located in the intron of the ATP6V1B2 gene, encoding the B subunit of the ATP-catalytic 
site containing the V1 cytosolic domain of the vacuolar proton pump-ATPase 11 which mediates 
acidification of various eukaryotic intracellular organelles such as lysosomes and endosomes, 
necessary for processes including protein sorting, receptor-mediated endocytosis and synaptic 
vesicle proton-gradient generation. The protonmotive force generated by vacuolar ATP-ases is used 
for various secondary reactions including synaptic vesicular reuptake, accumulation and storage 36, 37. 
Transport including retrieval and reemployment of synaptic vesicles is an essential component in the 
management and maintenance of neurotransmission. The vacuolar H+ ATP-ase plays a key role in the 
energization of regenerated synaptic vesicles after endocytosis, and thus in providing power for the 
replenishment of neurotransmitters via specific vesicular transporters 37, 38. Therefore generation of 
the electrochemical H+ gradient is essential and even its minor or partial disturbance may cause 
altered quantal neurotransmitter release 38, 39. Vacuolar ATPase inhibition was found to cause 
downregulation in important signaling pathways including Wnt and Notch, although it has not yet 
been clarified to what extent this effect is a consequence of its function in endosome acidification or 
whether it is due to its effect on endocytosis and trafficking 40. Vacuolar ATPase was also found to 
maintain neural stem cells in the developing cortex of mice 40. Although the role of vacuolar ATPase 
in central nervous system function is becoming clearer, no specific effect of this polymorphism on 
neuronal function has been specifically investigated. 
One possible mechanism by which variations in the vacuolar ATPase may exert its effect on 
depression risk is its role in oxidative stress, also implicated in the etiopathology of depression. 
Emotional stressors appear to induce inflammatory responses which are in turn associated with 
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increased proinflammatory cytokine production, stimulating reactive oxygen and nitrogen species 
production and leading to oxidative and nitrosative stress, free radical production and brain damage 
by increasing neurodegeneration and impairing neurogenesis 41. Chronic inflammation as well as 
oxidative and nitrosative stress has long been hypothesized to play a role in recurrent major 
depression and especially in neurocognitive deficits 31, 41. Cellular redox status may play a role in the 
regulation of the vacuolar H+ATPase hypothesized to be a redox sensor regulating neurotransmitter 
storage in response to growth factor signaling or oxidative stress, leading to decreased 
neurotransmitter amounts in vesicles and therefore decreased or diminished neurotransmitter 
release 42. In a more recent GWAS a suggestive association between serum myeloperoxidase levels 
and a region on chromosome 8p21.3 containing ATP6V1B2 genes was reported 43. Myeloperoxidase 
is a surrogate marker of prooxidative stress in major depression, and its serum levels were previously 
associated with depression 44. Myeloperoxidase expression was also reported to be associated with 
neurodegeneration, higher risk of Alzheimer’s disease 45, neuronal cell death, and neurogenesis 
inhibition 41. 
The brain shows enhanced vulnerability to oxidative damage as it uses large amounts of 
oxygen. Lipids, including unsaturated fatty acids which are especially reactible with free radicals are 
abundant in central nervous system cells. Furthermore, several brain regions are high in metal ions 
which promote reactive oxygen species formation, and lower antioxidant concentrations are 
observable in the brain compared to other body organs 41. The most sensitive to oxidative damage in 
the central nervous system are, among others, CA1 and CA4 hippocampal regions as well as the 
dorsal lateral striatum and III and V cortex layers 31 Especially CA1 neurons are highly vulnerable, 
playing a role in long-term memory and spatially related tasks 30, which corresponds to the deficit 
seen in our study. 
 
4.5 In silico functional analysis of rs1106634 and comparison with results of the Psychiatric Genetic 
Consortium GWAS  
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In silico functional prediction using the SNP Function Prediction Tool 
(http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm) showed no functional effects of our investigated 
SNP rs1106634, however, a nearby SNP with an LD of 0.62, namely the rs1042426, is a microRNA 
binding site which suggests that this genetic region may have functional consequences related to 
gene expression regulation. Furthermore, the latest mega-analysis of the Psychiatric Genetic 
Consortium demonstrated that SNPs in high LD (based on the CEU population data) with rs1106634, 
namely rs6586899 (r2=0.96) and rs4335136 (r2=0.86), showed nominally significant associations with 
major depressive disorder (rs6586899 p=0.004, rs4335136 p=0.017), while the functional rs1042426 
has a trend effect (p=0.089) supporting the weak but replicable role of ATP6V1B2 in lifetime 
depression 46.  
 
 
4.6 Limitations 
Several limitations of our study must be noted. We measured depressive symptoms and 
neurocognitive performance cross-sectionally. Both current and lifetime depression was based on 
self-report thus could be influenced by reporting and recalling bias. Recent life events possibly 
influencing current depression as well as general intellectual performance possibly impacting 
neurocognitive performance were not included in our models. Furthermore, our study sample is a 
general, non-epidemiological and non-representative population sample based on volunteers, 
therefore may be subject to sampling bias especially with respect to depression.  
 
4.7 Conclusion and implication for further studies 
The main finding of or study is supporting the role of the ATP6V1B2 rs1106634 A allele, implicated in 
depression GWAS-s with a suggestive significance, as a risk allele for lifetime but not current 
depression suggesting a role in the long-term development of affective illness. This finding is further 
underlined by the association of this SNP with neuroticism, a well-established risk factor of 
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depression, while the fact that neuroticism only partially mediated the association between 
rs1106634 and depression indicates a differential involvement of rs1106634 in these two 
phenomena. Our results also show that the effect of rs1106634 on lifetime risk of depression may be 
due to the association of the A allele with hippocampal dysfunction, thought to play a central role in 
the development of depression. We must also mention that while rs1106634 was implicated in 
several GWAS-s in psychiatric patients, it was not among the 15 genetic loci identified in major 
depression in a most recent study using an extremely large cohort with less intensive phenotyping 
approach using self-reported lifetime depression, 10 the same phenotype as used in our study.. 
On the clinical level our findings concerning the role of the vacuolar ATP-ase in depression and 
depression-associated cognitive deficits suggest that pharmacological interventions targeting this 
molecule may be promising new molecular agents in the treatment of depression in general and also 
in cases with more marked neurocognitive symptoms, also possibly able to tackle the progressive 
and degenerative nature of such symptoms. Our results thus emphasize the importance of looking 
beyond the monoaminergic systems in investigating mechanisms underlying depression in order to 
establish a more accurate model of this illness and pinpoint possible targets for pharmacological 
intervention, and also stress the importance of investigating polymorphisms implicated in depression 
GWAS-s, even if only with a weak effect, with respect to their possible role and mechanism.  
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Figure legends 
Figure 1. Linkage disequilibrium (LD) values (R2) and haplotype blocks of single nucleotide 
polymorphisms (SNPs) in and around the ATP6V1B2 gene 
 
The information is based on the CEU population of version 2 and release 24 of the HapMap project 
(http://hapmap.ncbi.nlm.nih.gov/).  
 
 
 
 
  
22 
 
Figure 2. Multivariate general linear models indicate a significant effect of ATP6V1B2 rs1106634 
genotype on PAL task performance but not on SOC task performance 
 
Multivariate general linear models for the three PAL variables (A) and the two SOC variables (B) with 
gender, age and lifetime depression, current (MADRS) depression and neuroticism as covariates. 
Means of standardized residuals for the PAL (A) and SOC (B) variables are displayed in function of 
ATP6V1B2 rs1106634 genotype. A allele carriers show a significantly lower memory score on the first 
trial (p<0.001), but a significantly higher total number of errors (p=0.003) and required trials 
(p=0.004) than those with GG genotype in the PAL task (A). However, the two genotype groups (A 
allele carriers and GG carriers) do not differ in the two aspects of SOC performance (SOC ITT p=0.435, 
SOC correct trial rate p=0.155) (B). 
 
PAL: Paired associates learning task; PAL memory score: memory score on the first trial of PAL; PAL 
errors: total number of errors on PAL; PAL required trials: total number of trials on PAL. SOC: 
Stockings of Cambridge task; SOC ITT: mean of all initial thinking times throughout the SOC task; SOC 
correct trial rate: rate of problems solved in minimum moves. Means (and the standard error of 
mean) of standardized residuals for the three PAL (A) and the two SOC (B) scores, partialling out 
variance accounted for by gender, age, lifetime depression, MADRS and neuroticism, are represented 
according to genotype. 
 
Table 1. Description of the samples and subsamples. 
  Level 1 Level 2
  
Budapest Manchester 
Budapest + 
Manchester 
Difference 
between 
Budapest 
and 
Manchester 
p Manchester 
gender female (%) 631 
(69.8%) 
922 (69.7%) 1553 
(69.8%) 
χ2=0.001 0.977 142 (68.9%)
male (%) 273 
(30.2%) 
400 (30.3%) 673 (30.2%) 64 (31.1%)
ATP6V1B2 
rs1106634 
AA (%) 12 (1.3%) 28 (2.1%) 40 (1.8%) χ2=10.445 0.005 7 (3.4%)
GA (%) 184 
(20.4%) 
337 (25.5%) 521 (23.4%) 35 (17.0%)
GG (%) 708 
(78.3%) 
957 (72.4%) 1665 
(74.8%) 
164 (79.6%)
lifetime 
depression 
reported 
(%) 
197 
(21.8%) 
740 (56.0%) 937 (42.1%) χ2=257.378 <0.001 108 (52.4%)
not 
reported 
(%) 
707 
(78.2%) 
582 (44.0%) 1289 
(57.9%) 
98 (47.6%)
age (mean ± SEM) 31.24 
(0.353) 
34.03 (0.282) 32.90 
(0.222) 
t=-6.216 <0.001 32.41 
(0.730) 
BSI depression score 
(mean ± SEM) 
0.57 
(0.023) 
1.07 (0.028) 0.87 (0.020) t=-13.744 <0.001 
MADRS depression score 
(mean ± SEM) 
  4.58 (0.493)
neuroticism score (mean 
± SEM) 
2.84 
(0.028) 
3.36 (0.025) 3.15 (0.019) t=-13.922 <0.001 93.04 
(1.957) 
PAL memory score (mean 
± SEM) 
    21.03
(0.251) 
PAL errors (mean ± SEM)     7.57 (0.625)
PAL required trials (mean 
± SEM) 
    10.76 
(0.219) 
SOC ITT (mean ± SEM) 
(milliseconds) 
    5709.34 
(306.745) 
SOC correct trial rate 
(mean ± SEM) 
    0.74 (0.011)
SEM: standard error of mean; BSI: Brief Symptom Inventory; MADRS: Montgomery-Åsberg 
Depression Rating Scale; PAL: Paired associates learning task; PAL memory score: memory score on 
the first trial of PAL; PAL errors: total number of errors on PAL; PAL required trials: total number of 
trials on PAL; SOC: Stockings of Cambridge task; SOC ITT: mean of all initial thinking times throughout 
the SOC task; SOC correct trial rate: rate of problems solved in minimum moves; χ2: Pearson chi-
square. 
 
 
 
Table 2. Main effect of ATP6V1B2 rs1106634 on the two depression phenotypes in our Level-1 
sample (Manchester and Budapest combined sample) 
 Lifetime depression BSI depression score 
Model N OR 95% CI t p N Beta SE t p 
Additive 2226 1.406 1.165-
1.696 
3.560 <0.001 2222 0.048 0.039 1.214 0.225 
Dominant 2226 1.465 1.189-
1.804 
3.591 <0.001 2222 0.042 0.044 0.965 0.335 
Recessive 2226 1.527 0.779-
2.993 
1.234 0.217 2222 0.179 0.142 1.255 0.210
BSI: Brief Symptom Inventory; OR: odds ratio; 95% CI: 95% confidence interval of OR; SE: standard 
error of beta; p: nominal p-value. Population (Budapest or Manchester), gender and age were 
covariates in all of the six regression equations. The three models correspond to that A is the minor 
allele in all cases. Significant findings according to the Bonferroni corrected threshold (p≤0.0083) are 
marked with bold. 
 
 
Table 3. Main effect of ATP6V1B2 rs1106634 on lifetime depression in the two Level-1 subsamples 
in Manchester and Budapest 
 Budapest Manchester 
Model N OR 95% CI t p N OR 95% CI t p
Additive 904 1.541 1.109-2.142 2.574 0.010 1322 1.342 1.070-
1.682 
2.549 0.011
Dominant 904 1.628 1.129-2.348 2.609 0.009 1322 1.387 1.079-
1.784 
2.549 0.011
OR: odds ratio; 95% CI: 95% confidence interval of OR; p: nominal p-value. Gender and age were 
covariates in all of the four regression equations. The models correspond to that A is the minor allele 
in both subsamples. All findings are nominally significant (p≤0.05). 
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allele carriers and GG carriers) do not differ in the two aspects of SOC performance (SOC ITT p=0.435, 
SOC correct trial rate p=0.155) (B). 
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correct trial rate: rate of problems solved in minimum moves. Means (and the standard error of 
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